Meta-Analysis
Copyright ©The Author(s) 2024.
World J Virol. Mar 25, 2024; 13(1): 88660
Published online Mar 25, 2024. doi: 10.5501/wjv.v13.i1.88660
Table 1 Main characteristic of included studies
Ref.CountryDesignSample sizeMale %Severity of COVID-19Bamlanivimab
Comparison(s)
n
Mean age
Comorbidity1
Name
n
Mean age
Comorbidity1
Alam et al[19], 2021United StatesRS26444MM1608158.1SOC868451.2
Bariola et al[13], 2021United StatesRS139244.39MM23267.375.9SOC116067.173.6
Brock et al[20], 2021United StatesRS108NAMM58NA100SOC58NA100
Chen et al[21], 2021United StatesRCT2454MC18NANAPBO643.2NA
Chen et al[21], 2021United StatesRCT45244.9MM3094569.6PBO1434666.4
Chew et al[23], 2022United StatesRCT31751.1MS159NANAPBO158NANA
Cooper et al[24], 2021United StatesRS575845.13NA17186056.3SOC, B/E, C/I4040NA> 50
Corwin et al[25], 2021United StatesRS611742.7MM78062.668.1SOC533756.747.1
Destache et al[14], 2021United StatesRS23447MM1177269.2SOC1177263.3
Djuric et al[26], 2022SerbiaRS3167.74MS1362.230.8SOC1865.938.9
Farcy et al[11], 2022United StatesPS32160.12MM20164.256.2C/I12066.358.3
San Filippo et al[39], 2022United StatesRS45347.01MM18366.944.8C/I27063.451.9
Ganesh et al[27], 2021United StatesRS467050.62MM23356354.2SOC23356355.1
Ganesh et al[28], 2021United StatesRS359650.02MM2747NA53.3C/I849NA48.3
Gottlieb et al[29], 2021United StatesRCT57745.40MM309NANRPBO, B/E156NANA
Heller et al[31], 2023GermanyRS2645MM1081NRSOC, C/I23NANA
Iqbal et al[8], 2021United StatesRS284NAMM144NR10.3SOC140NA63.60
Karr et al[10], 2022United StatesRS4663.04MM406965SOC66950
Kumar et al[32], 2022United StatesRS40352.10MM2186650.5SOC1856243.8
ACTIV-3/TICO LY-CoV555 Study Group et al[30], 2021United StatesRCT31457.32NA1636372PBO1515965
McCreary et al[33], 2021United StatesRCT193546.20MM1285747B/E, C/I1807NANA
Monday et al[34], 2022United StatesRCT64342.76MM2946172.8B/E3495572.4
Murillo et al[35], 2022United StatesRS10742.99MM39NANASOC63NANA
Priest et al[36], 2022United StatesRS75849MM379NA88SOC379NA88
Quenzer et al[37], 2022United StatesRS27051.85MM13460.392.5SOC13663.369.1
Rubin et al[38], 2021United StatesRS125743.75NA19164NRSOC106664.6NA
Savoldi et al[40], 2022ItalyPS63561.57MM1616372.7B/E, C/I474NRNA
Sridhara et al[41], 2023United StatesRS218242.98NA10996452.8SOC10914620.9
Voelker and Jerath[42], 2022United StatesPS67843.65NA380NANAC/I298NANA
Webb et al[43], 2021United StatesQES1353455.19NA4796590.8SOC, C/I5651NANA
Table 2 Subgroup and sensitivity analyses for efficacy and safety outcomes
AnalysisStudies, nSample size, nPoint estimate (95%CI)P valueHeterogeneity
Q value
P value
I2
Sensitivity analysis
Mortality rate soc (excluding Brock 2021and Djuric 2021)16290910.52 (0.37-0.73)< 0.00118.450.2418.71
Hospitalization rate (excluding Brock 2021)17265650.55 (0.42-0.71)< 0.00169.650.2177.02
Hospitalization rate (excluding Voelker 2022)781771.38 (1.00-1.92)0.0414.250.0257.91
ICU admission (excluding Brock 2021)6157590.88 (0.60-1.29)0.527.790.1635.81
Subgroup analysis
Hospitalization rate by design, BAM vs SOC/PBO
OS16259040.67 (0.60-0.75)< 0.00182.27< 0.00181.76
RCT27690.44 (0.21-0.94)0.031.950.1648.80
Hospitalization rate by sample size, BAM vs SOC/PBO
< 100011234530.51 (0.43-0.61)< 0.00150.51< 0.00180.20
≥ 1000732200.77 (0.67-0.89)< 0.00122.220.00173.00
Hospitalization rate by mean age, BAM vs SOC/PBO
< 658227830.77 (0.67-0.88)< 0.00126.91< 0.00173.99
≥ 65419180.46 (0.32-0.66)< 0.0010.300.96< 0.001
Mortality rate by design, BAM vs SOC/PBO
OS17289160.44 (0.31-0.62)< 0.00114.670.540.00
RCT13141.67 (0.57-4.86)0.340.001.000.00
Mortality rate by sample size, BAM vs SOC/PBO
< 10001240300.48 (0.31-0.76)0.00215.550.1529.29
≥ 10006252000.51 (0.31-0.84)0.0094.430.480.00
Mortality rate by mean age, BAM vs SOC/PBO
< 658256390.60 (0.37-0.96)0.0379.890.1929.26
≥ 65521890.40 (0.20-0.79)0.0085.160.2722.53